Skip to content

US treatment guidelines updated

Fixed-dose ARV combinations: choices and challenges

Adherence, not baseline CD4 cell count, linked to CD4 cell gain on HAART

Genetic analysis suggests control of inflammation could help some delay HIV treatment

NNRTI-based HAART effective and safe for primary HIV infection

PEP for sexual exposure to HIV not 100% effective

HAART clinically and immunologically effective in babies but high rate of virologic failure

Nevirapine should not be used for PEP confirms US review

Meta-analysis finds PI-based HAART better than NNRTI regimens in NRTI experienced